Dementia and Alzheimer Disease

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Jayeeta Basu, PhD, an assistant professor in the departments of Psychiatry and Neuroscience at NYU Langone, commented on how newly decoded entorhinal–hippocampal circuits stabilize memory maps during learning.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed in October 2025, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

A study reveals that genetic counseling significantly empowers individuals at risk for frontotemporal dementia, highlighting the need for best practice guidelines.

Axsome Therapeutics advances AXS-05 for Alzheimer agitation, showcasing promising trial results and potential for treating major depressive disorder.

Brad Racette, MD, FAAN, the Kemper and Ethel Marley Chair for Neurology at Barrow Neurological Institute, discussed his keynote lecture on the neurologic health effects of electric vehicles and the global implications of environmental exposure.

Gregory Hawryluk, MD, PhD, a neurosurgeon at Cleveland Clinic, spoke on the development and clinical impact of new global guidelines for penetrating traumatic brain injury.

The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.

A recent study highlights the increased mortality risk linked to benzodiazepine and antipsychotic use in hospice patients with dementia, urging new prescribing guidelines.

A recent meta-analysis reveals frontotemporal dementia's incidence and prevalence, highlighting its significance in clinical research and treatment advancements.

The FDA has granted fast track designation to Eisai’s etalanetug, an anti-tau antibody targeting tau pathology in Alzheimer's disease.

Beth McQuiston, MD, neurologist and medical director in Abbott’s diagnostics business, discussed the clinical value of Abbott’s FDA-cleared i-STAT TBI test as it was named to TIME’S 2025 Best Inventions List.

Roche's Elecsys pTau181 test receives FDA clearance, revolutionizing Alzheimer diagnosis in primary care with a minimally invasive blood test.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Neflamapimod treatment led to slowing of clinical worsening, as assessed by Clinical Dementia Rating-Sum of Boxes, when drug concentrations were achieved.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Bristol Myers Squibb's BMS-986446 receives FDA fast track designation, targeting tau protein to combat early-stage Alzheimer's disease in ongoing trials.

Eli Lilly's donanemab gains EU approval, offering hope for early Alzheimer's treatment with a new dosing regimen that reduces side effects.

Xu Li, PhD, a research associate in the F.M. Kirby Research Center for Functional Brain Imaging at Kennedy Krieger Institute, provided commentary on a promising, recently published study using QSM MRI to detect cognitive changes in Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.